Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 15/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686332 | 0.87 | IDH1 (0.42) | IDH1HRH4CHRM3PDE4APDE4B | |
| SCHEMBL19687391 | 0.87 | IDH1 (0.42) | IDH1CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL19686668 | 0.87 | IDH1 (0.42) | IDH1HRH4CHRM3PDE4APDE4B | |
| SCHEMBL19686960 | 0.82 | IDH1 (0.41) | IDH1IDH2NAPEPLD | |
| SCHEMBL19686560 | 0.82 | IDH1 (0.41) | IDH1CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL31127338 | 0.82 | IDH1 (0.41) | IDH1IDH2NAPEPLD | |
| SCHEMBL21144159 | 0.80 | IDH1 (0.42) | IDH1 | |
| SCHEMBL19687209 | 0.80 | IDH1 (0.42) | IDH1HRH4CHRM3PDE4APDE4B | |
| SCHEMBL19687320 | 0.80 | IDH1 (0.47) | IDH1IDH2 | |
| SCHEMBL19686558 | 0.80 | IDH1 (0.47) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885HRH4 2164/4885CHRM3 631/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885HRH4 2164/4885CHRM3 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.